ProCE Banner Activity

New Trends and Recommendations in the Management of HABP/VABP and Gram-Negative Resistance

Clinical Thought
HABP and VABP are extremely challenging infections to manage for various reasons. Here’s my take on how new recommendations and tools can help lead to early effective therapy.

Released: January 24, 2022

Expiration: January 23, 2023

Share

Faculty

Keith S. Kaye

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Keith S. Kaye, MD, MPH

Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

Keith S. Kaye, MD, MPH, has disclosed that he has served as a consultant for Actavis, Allecra, Bayer, Carb-X, Cipla, Clarametyx Biosciences, Contrafect, Cubist, Entasis, Integrated Operations, Melinta, Merck, Nabriva, NS Nanotech, Pratek, QPex, SPERO, Shionogi Inc, UtilityTherapeutics, VenatoRX, and Xellia.